Stockholders' Equity | Stockholders’ Equity: The Company's common shares have rights to any dividend declared by the board of directors (the "Board"), subject to any preferential or other rights of any outstanding preferred stock, and voting rights to elect all current members of the Board. The Company has 80,000,000 shares of authorized preferred stock, par value $0.001 per share. The preferred shares have preferential rights over the common shares with respect to dividends and net distribution upon liquidation. The Company did not issue any preferred shares as of March 31, 2019 . At March 31, 2019 and December 31, 2018 , the adjusted closing price of Verisk common stock was $133.00 and $108.83 per share, respectively. On February 13, 2019, the Company’s Board of Directors approved a cash dividend of $0.25 per share of common stock issued and outstanding to the holders of record as of March 15, 2019. The cash dividend of $40.9 million was paid on March 29, 2019 and recorded as a reduction to retained earnings. On April 29, 2019, the Company's Board of Directors approved a cash dividend of $0.25 per share of common stock issued and outstanding, payable on June 28, 2019, to the holders of record as of June 14, 2019. The dividend is recorded, subsequent to March 31, 2019 as a reduction to retained earnings and will be adjusted for actual payments. Share Repurchase Program Since May 2010, the Company has authorized repurchases of up to $3,300.0 million of its common stock through its Repurchase Program. The Company has repurchased shares with an aggregate value of $2,947.4 million . The Company repurchased 636,590 shares of common stock with an aggregate value of $75.0 million during the three months ended March 31, 2019 . As of March 31, 2019 , the Company had $352.6 million available to repurchase shares through its Repurchase Program. In December 2018, the Company entered into an Accelerated Share Repurchase ("ASR") agreement to repurchase shares of its common stock for an aggregate purchase price of $75.0 million with Morgan Stanley & Co. LLC. The ASR agreement is accounted for as a treasury stock transaction and a forward stock purchase agreement indexed to the Company's common stock. The forward stock purchase agreement is classified as an equity instrument under ASC 815-40, Contracts in Entity's Own Equity ("ASC 815-40") and was deemed to have a fair value of zero at the effective date. Upon payment of the aggregate purchase price on January 2, 2019, the Company received an aggregate delivery of 636,590 shares of its common stock at a price of $117.82 per share during the three months ended March 31, 2019 . The aggregate purchase price was recorded as a reduction to stockholders' equity in the Company's condensed consolidated statements of changes in stockholders' equity for the three months ended March 31, 2019 . These 636,590 shares resulted in a reduction of outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted earnings per share ("EPS"). In March 2019, the Company entered into an additional ASR agreement with Morgan Stanley & Co. LLC to repurchase shares of its common stock for an aggregate purchase price of $50.0 million . Upon payment of the aggregate purchase price on April 1, 2019, the Company received an initial delivery of 300,752 shares of its common stock at a price of $133.00 per share, representing approximately $40.0 million of the aggregate purchase price. Upon the final settlement of the ASR agreement in June 2019, the Company may be entitled to receive additional shares of its common stock or, under certain limited circumstances, be required to deliver shares to the counter-party. Treasury Stock As of March 31, 2019 , the Company’s treasury stock consisted of 380,350,444 shares of common stock. During the three months ended March 31, 2019 , the Company reissued 318,774 shares of common stock from the treasury shares at a weighted average price of $9.54 per share. Earnings Per Share Basic EPS is computed by dividing net income by the weighted average number of common shares outstanding during the period. The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding, using the treasury stock method, if the dilutive potential common shares, including vested and nonvested stock options, nonvested restricted stock awards, nonvested restricted stock units, nonvested performance awards, consisting of performance share units (“PSU”), and nonvested deferred stock units, had been issued. The following is a presentation of the numerators and denominators of the basic and diluted EPS computations for the three months ended March 31, 2019 and 2018 : Three Months Ended March 31, 2019 2018 Numerator used in basic and diluted EPS: Net income $ 134.4 $ 133.0 Denominator: Weighted average number of common shares used in basic EPS 163,528,343 165,043,047 Effect of dilutive shares: Potential common shares issuable from stock options and stock awards 3,016,602 3,949,488 Weighted average number of common shares and dilutive potential common 166,544,945 168,992,535 The potential shares of common stock that were excluded from diluted EPS were 49,820 and 3,718 for the three months ended March 31, 2019 and 2018 , respectively, because the effect of including these potential shares was anti-dilutive. Accumulated Other Comprehensive Losses The following is a summary of accumulated other comprehensive losses as of March 31, 2019 and December 31, 2018 : 2019 2018 Foreign currency translation adjustment $ (430.0 ) $ (488.5 ) Pension and postretirement adjustment, net of tax (102.3 ) (103.4 ) Accumulated other comprehensive losses $ (532.3 ) $ (591.9 ) The before tax and after tax amounts of other comprehensive income for the three months ended March 31, 2019 and 2018 are summarized below: Before Tax Tax (Expense) Benefit After Tax For the Three Months Ended March 31, 2019 Foreign currency translation adjustment $ 58.5 $ — $ 58.5 Pension and postretirement adjustment before reclassifications 2.8 (0.7 ) 2.1 Amortization of net actuarial loss and prior service benefit (1) (1.3 ) 0.3 (1.0 ) Pension and postretirement adjustment 1.5 (0.4 ) 1.1 Total other comprehensive gain $ 60.0 $ (0.4 ) $ 59.6 For the Three Months Ended March 31, 2018 Foreign currency translation adjustment $ 102.7 $ — $ 102.7 Pension and postretirement adjustment before reclassifications 2.1 (0.5 ) 1.6 Amortization of net actuarial loss and prior service benefit (1) (0.9 ) 0.3 (0.6 ) Pension and postretirement adjustment 1.2 (0.2 ) 1.0 Total other comprehensive gain $ 103.9 $ (0.2 ) $ 103.7 _______________ (1) These accumulated other comprehensive loss components, before tax, are included under “Cost of revenues” and “Selling, general and administrative” in the accompanying condensed consolidated statements of operations. These components are also included in the computation of net periodic (benefit) cost (see Note 12 Pension and Postretirement Benefits for additional details). |